EZH2 and prostate carcinoma: miR-26a influences cell cycle progression in Burkitt’ lymphoma cell lines by targeting EZH2 [238], while miR-101 attenuates cell proliferation in bladder transitional carcinoma and prostate cancer cell lines [239,240].